Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer. (Q52875446)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

ChEBI release 2020-05-28

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

Masafumi Ikeda

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Hideaki Takahashi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Shunsuke Kondo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Michael Mauritius Fabio Lahn

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Karim A Benhadji

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Hisaki Fujii

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Hideki Ueno

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

publication date

27 April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

19 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

79

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

1169-1177

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00280-017-3313-x

19 March 2020

exact match

0 references

cites work

Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3313-X

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3313-X

Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3313-X

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3313-X

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3313-X

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3313-X

TGF-beta/SMAD signaling and its involvement in tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3313-X

LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3313-X

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3313-X

10.1007/S00280-017-3313-X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28451833%20AND%20SRC:MED&resulttype=core&format=json

release_uui4sc5va5gn5pu3w5j6767iui

19 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uui4sc5va5gn5pu3w5j6767iui

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference